ES3059456T3 - Substituted heterocyclic compounds - Google Patents

Substituted heterocyclic compounds

Info

Publication number
ES3059456T3
ES3059456T3 ES22727681T ES22727681T ES3059456T3 ES 3059456 T3 ES3059456 T3 ES 3059456T3 ES 22727681 T ES22727681 T ES 22727681T ES 22727681 T ES22727681 T ES 22727681T ES 3059456 T3 ES3059456 T3 ES 3059456T3
Authority
ES
Spain
Prior art keywords
compounds
compound
mmol
disease
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES22727681T
Other languages
English (en)
Spanish (es)
Inventor
Steven H Spergel
Ryan M Moslin
Michael Edward Mertzman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES3059456T3 publication Critical patent/ES3059456T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES22727681T 2021-05-14 2022-05-13 Substituted heterocyclic compounds Active ES3059456T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163188498P 2021-05-14 2021-05-14
US202263318508P 2022-03-10 2022-03-10
PCT/US2022/029117 WO2022241174A1 (en) 2021-05-14 2022-05-13 Substituted heterocyclic compounds

Publications (1)

Publication Number Publication Date
ES3059456T3 true ES3059456T3 (en) 2026-03-20

Family

ID=81927791

Family Applications (1)

Application Number Title Priority Date Filing Date
ES22727681T Active ES3059456T3 (en) 2021-05-14 2022-05-13 Substituted heterocyclic compounds

Country Status (12)

Country Link
US (2) US11884650B2 (https=)
EP (1) EP4337648B1 (https=)
JP (1) JP7818623B2 (https=)
KR (1) KR20240008338A (https=)
AU (1) AU2022272725A1 (https=)
BR (1) BR112023023726A2 (https=)
CA (1) CA3218579A1 (https=)
ES (1) ES3059456T3 (https=)
IL (1) IL308422A (https=)
MX (1) MX2023013351A (https=)
TW (1) TW202311248A (https=)
WO (1) WO2022241174A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12492184B2 (en) 2020-12-22 2025-12-09 InventisBio Co., Ltd. Heteroaryl compounds, preparation methods and uses thereof
CA3208361A1 (en) 2021-02-19 2022-08-25 Anjali Pandey Tyk2 inhibitors and uses thereof
EP4294806A1 (en) 2021-02-19 2023-12-27 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
AU2022222470A1 (en) 2021-02-19 2023-09-21 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
KR20240008337A (ko) * 2021-05-14 2024-01-18 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물
US20240317718A1 (en) * 2021-05-14 2024-09-26 Bristol-Myers Squibb Company Substituted heterocyclic compounds
JP2024518791A (ja) * 2021-05-14 2024-05-02 ブリストル-マイヤーズ スクイブ カンパニー 置換ヘテロ環化合物
CN118812511A (zh) * 2023-04-21 2024-10-22 浙江文达医药科技有限公司 作为tyk2抑制剂的杂环化合物及合成和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102233252B1 (ko) * 2012-11-08 2021-03-26 브리스톨-마이어스 스큅 컴퍼니 IL-12, IL-23 및/또는 IFNα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물
JP7631193B2 (ja) * 2018-10-22 2025-02-18 アルミス インコーポレイテッド Tyk2阻害剤およびその使用
AU2019373203B2 (en) * 2018-10-30 2024-10-24 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha
AU2021254764A1 (en) * 2020-04-14 2022-11-03 Gossamer Bio Services, Inc. Substituted pyridines for the treatment of inflammatory diseases
KR20240008337A (ko) * 2021-05-14 2024-01-18 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물
US20240317718A1 (en) * 2021-05-14 2024-09-26 Bristol-Myers Squibb Company Substituted heterocyclic compounds
PE20250262A1 (es) * 2021-05-14 2025-01-29 Bristol Myers Squibb Co Compuestos heterociclicos sustituidos
JP2024518791A (ja) * 2021-05-14 2024-05-02 ブリストル-マイヤーズ スクイブ カンパニー 置換ヘテロ環化合物

Also Published As

Publication number Publication date
EP4337648B1 (en) 2025-12-24
AU2022272725A1 (en) 2024-01-04
IL308422A (en) 2024-01-01
MX2023013351A (es) 2023-11-27
EP4337648A1 (en) 2024-03-20
KR20240008338A (ko) 2024-01-18
JP2024518555A (ja) 2024-05-01
US11884650B2 (en) 2024-01-30
WO2022241174A1 (en) 2022-11-17
TW202311248A (zh) 2023-03-16
US20240124421A1 (en) 2024-04-18
US20220388987A1 (en) 2022-12-08
BR112023023726A2 (pt) 2024-01-30
JP7818623B2 (ja) 2026-02-20
CA3218579A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
ES3059456T3 (en) Substituted heterocyclic compounds
KR102782807B1 (ko) Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
ES2907008T3 (es) Compuestos de heteroarilo sustituidos con fosfinóxido alquilamida como moduladores de respuestas de IL-12, IL-23 y/o IFN alfa
JP2024518554A (ja) 置換ヘテロ環化合物
ES3035735T3 (en) Amide-disubstituted pyridine or pyridazine compounds
KR102477063B1 (ko) Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물
US20240270723A1 (en) Substituted heterocyclic compounds
EP4337650A1 (en) Substituted heterocyclic compounds
CN104903301A (zh) 可用于调节IL-12、IL-23和/或IFNα的烷基酰胺取代的嘧啶化合物
CN117321045A (zh) 经取代的杂环化合物
EA047032B1 (ru) Замещенные гетероциклические соединения
CN117355514A (zh) 经取代的杂环化合物
KR20250099236A (ko) 치환된 헤테로시클릭 화합물
BR112023023425B1 (pt) Compostos heterocíclicos substituídos, composição farmacêutica que os compreende, e usos dos mesmos